By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Hematologic Diseases. According to news reporting originating from Genoa, Italy, by NewsRx correspondents, research stated, "Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to single-center experience with limited numbers of patients. We analyzed results in 795 patients with FA who underwent first HSCT between May 1972 and January 2010."
Our news editors obtained a quote from the research from Gaslini Institute, "With a 6-year median follow-up, overall survival was 49% at 20 years (95% confidence interval, 38-65 years). Better outcome was observed for patients transplanted before the age of 10 years, before clonal evolution (ie, myelodysplastic syndrome or acute myeloid leukemia), from a matched family donor, after a conditioning regimen without irradiation, the latter including fludarabine. Chronic graft-versus-host disease and secondary malignancy were deleterious when considered as time-dependent covariates. Age more than 10 years at time of HSCT, clonal evolution as an indication for transplantation, peripheral blood as source of stem cells, and chronic graft-versus-host disease were found to be independently associated with the risk for secondary malignancy."
According to the news editors, the research concluded: "Changes in transplant protocols have significantly improved the outcome of patients with FA, who should be transplanted at a young age, with bone marrow as the source of stem cells."
For more information on this research see: Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood, 2013;122(26):4279-4286. Blood can be contacted at: Amer Soc Hematology, 2021 L St NW, Suite 900, Washington, DC 20036, USA. (American Society of Hematology - www.hematology.org/; Blood - bloodjournal.hematologylibrary.org/)
The news editors report that additional information may be obtained by contacting R.P. de Latour, HematolG Gaslini Inst, Genoa, Italy. Additional authors for this research include R. Porcher, J.H. Dalle, M. Aljurf, E.T. Korthof, J. Svahn, R. Willemze, C. Barrenetxea, V. Mialou, J. Soulier, M. Ayas, R. Oneto, A. Bacigalupo, J.C.W. Marsh, C. Peters, G. Socie and C. Dufour (see also Hematologic Diseases).
Keywords for this news article include: Genoa, Europe, Surgery, Hypoplastic, Fanconi Anemia, Bone Marrow Cells, Congenital Anemia, Metabolic Diseases, Stem Cell Research, Bone Marrow Diseases, Cell Transplantation, Hematologic Diseases, Hematopoietic Stem Cells, Hemic and Lymphatic Diseases, DNA Repair-Deficiency Disorders
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC